Tolka is an AI-native biotech. We are building the SWIFT Platform, which brings together LLM agents to author FDA-compliant batch records, robotics to perform manual laboratory work, and predictive models to learn from patient outcomes and continuously improve treatment efficacy.
At Tolka AI Therapeutics, we are revolutionizing phage therapy with bespoke, personalized cocktails designed to precisely target hard-to-treat infections such as Mycobacterium abscessus. By leveraging patient-specific isolates, we develop GMP-grade phages that are trained and optimized to effectively eliminate the pathogenic strain, offering a tailored therapeutic solution. Our phage formulations are designed for stability at 4°C, ensuring ease of use for patients.
Where a traditional manufacturing cell relies on a director, managers, operators, and QA verifiers, a Tolka cell is designed to replace most of that headcount with agents and robots. The platform is built to iterate on 10,000 small batches per year versus 1 to 3 at a conventional plant, so each therapy can be tailored to the individual patient.